Borderline Personality Disorder
Conditions
Keywords
Borderline Personality Disorder, Personality Disorders
Brief summary
This study evaluates the effect of 5Hz repetitive Transcranial Magnetic Stimulation (rTMS) on Dorsomedial Prefrontal Cortex on Borderline Personality Disorder (BPD).
Detailed description
Borderline Personality Disorder (BPD) is a mental illness with a high worldwide prevalence and economic costs, and is characterized with impulsiveness, both interpersonal relationships and emotional disturbance. Symptoms are related to hypofunction of frontal areas like Dorsomedial Prefrontal Cortex (DMPFC). Psychotherapy is the base treatment in this disease, but economic costs and long-time therapy have made difficult the attachment. Repetitive Transcranial Magnetic Stimulation(rTMS), authorized by Food and Drug Administration (FDA) on Major Depressive Disorder (MDD) treatment has proven good results in previous works in BPD clinical characteristics on both dorsolateral prefrontal cortex (DLPFC) and enhancement in depressive symptoms stimulating DMPFC in high frequency. However, there are no current research that have addressed the use of low-frequency on this anatomical area.
Interventions
DEVICERepetitive Transcranial Magnetic Stimulation
Subjects will receive both active and placebo rTMS, in a crossover modality.
Sponsors
Universidad Autonoma de Queretaro
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Masking description
Single
Intervention model description
The aim of this study is to evaluate the clinical effects of 5Hz rTMS over Dorsomedial Prefrontal Cortex on an active versus placebo modality stimulation.
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
No
Inclusion criteria
* 18-45 years old. * Meet DSM 5 (Diagnostic and Statistical Manual, 5th edition) diagnostic criteria for Borderline Personality Disorder. * Score of \>7 in the Diagnostic Interview for Borderline (Revised version, DIB-R) * All patients must have follow-up psychotherapy of at least one month. * No changes on pharmacological treatment within the last month. * Patients must provide their oral and written informed consent.
Exclusion criteria
* Subjects with history of traumatic brain injury with loss of consciousness. * Subjects with intracranial metallic objects or metal plates in the skull. * Subjects diagnosed with uncontrolled chronic (for example: hypertension, diabetes) or neurological diseases. * Comorbidity with other mental illness. (Except Depressive symptoms and Anxiety Disorders). * Presence of psychotic symptoms. * Alterations in the electroencephalogram (epileptiform activity). * Self injury or suicidal attempts in less than 2 weeks (depends on the severity and deepness).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Borderline Symptoms List (BSL) | 6 weeks | BSL is a 23 item scale that evaluates the general symptoms and 11 items with behavioural evaluation of BPD. |
| Global Clinical Impression of BPD (GCI-BPD) | 6 weeks | CGI-BPD is a 10 item evaluation that rates the severity of BPD distributed in 9 neuropsychological domains with a final global score. |
| Borderline Evaluation of Severity Over Time (BEST) | 6 weeks | BEST is a 15 item scale that evaluates the severity in this pathology according to 3 areas: thoughts, emotions and typical behaviours. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Hamilton Depression Rating Scale (HDRS) | 6 weeks | HDRS is a 21 item scale that evaluates the severity of depressive symptoms in patients. |
| Hamilton Anxiety Rating Scale (HARS) | 6 weeks | HARS is a 14 items rating scale that evaluates the severity of anxiety symptoms in patients. |
| Barratt Impulsivity Scale (BIS-11) | 6 weeks | The Barratt Impulsiveness Scale is a questionnaire designed to assess the personality / behavioral construct of impulsiveness; composed of 30 items describing common impulsive or non-impulsive (for reversed scored items) behaviors and preferences . |
Countries
Mexico
Contacts
Primary ContactAngel R Calderón-Moctezuma, Physician
Outcome results
None listed